---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034701"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:41:12.271227+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics reports FY2023 net loss $62.7M; ENLIGHTEN I Phase 3 topline expected Q2 2024

## Summary
- Net loss $62.7M in FY2023 ($15.1M Q4); R&D $48.0M, G&A $19.1M; cash $102.8M, runway into Q1 2025.
- Topline results from ENLIGHTEN I Phase 3 trial of LYR-210 in CRS anticipated Q2 2024.
- ENLIGHTEN II enrollment completion expected H2 2024; ENLIGHTEN I 52-week extension results Q4 2024.
- BEACON Phase 2 of LYR-220 met safety endpoint; significant SNOT-22 (−16.8; p=0.007) and 3CS (−1.50; p=0.02) improvement vs sham at week 24.

## SEC filing metadata
- accession: 0000950170-24-034701
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/0000950170-24-034701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/lyra-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034701
- JSON: https://secwatch.observer/filing/0000950170-24-034701.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034701.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: announced its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017024034701/0000950170-24-034701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.